Skip to main content

Takeda in talks with Shire after $61 billion bid rejected

LONDON/NEW YORK (Reuters) - Japan's Takeda Pharmaceutical is in negotiations with Shire after making a third takeover bid worth around $61 billion that was rejected by the London-listed rare diseases drugmaker.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.